Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
rated new Neutral at Credit Suisse. $10 price target. Company will likely see muted growth, relative to its peers.
Bed Bath & Beyond
rated new Neutral at Robert Baird. $48 price target. Company is a best-of-breed retailer, but margins already appear to be at peak levels.
downgraded at Keybanc from Buy to Hold. Valuation call.
downgraded at Barclays to Equal-weight. $53 price target. Market is already pricing in a strong earnings report next week.
upgraded at BofA/Merrill from Underperform to Neutral. $7.50 price target. Funding risks are priced into the stock, and Sprint is not likely to walk away from the company.
upgraded at Goldman from Neutral to Buy. $117 price target. Stock was also added to the Conviction List. Estimates increased, as the company has strong operating momentum.
downgraded at Morgan Stanley from Overweight to Equal-weight. Estimates also reduced through 2011.
upgraded at Piper from Neutral to Overweight. $58 price target. Office visit trends are improving.
upgraded at Piper from Neutral to Overweight. $22 price target. Company has multiple potential catalysts.
rated new Neutral at Janney Montgomery. $55 price target. Stock is already pricing in a global sales recovery.
rated new Neutral at Credit Suisse. $12 price target. Diversified business model could limit the company's growth and margin potential.
upgraded at Argus from Hold to Buy, Argus Research said. $17 price target. Company is seeing higher demand.
downgraded at Citigroup to Hold. $95 price target. Potential menthol regulations continue to hang over the stock.
downgraded at Morgan Stanley from Overweight to Equal-weight. Domestic growth headwinds remain.
downgraded at Citigroup to Hold. Valuation call, based on a $27 price target.
downgraded at Morgan Stanley from Overweight to Equal-weight. Valuation call, based on a $17 price target.
rated new Overweight at Morgan Stanley. $25 price target. Company should continue to expand its margins over the next several quarters.
downgraded at Morgan Stanley from Overweight to Equal-weight. Company likely will not see above-average growth until 2012.
upgraded at Needham from Hold to Buy. $16 price target. Company should regain GPU market share and see Tegra ramp in 2011.
estimates, target boosted at Citigroup. Shares of NVDA now seen reaching $17. Estimates also upped, to match the company's new guidance. Buy rating.
rated new Equal-weight at Morgan Stanley. Copaxone will face generics threats.
rated new Hold at Jefferies. $40 price target. Company is gaining market share, but faces pricing pressure.
rated new Hold at Citigroup. Coverage of UPL was initiated with a Hold rating. $50 price target. Rockies growth could slow in the new year.
downgraded at JP Morgan from Overweight to Neutral. $33 price target. Company may find it more difficult to pass along higher input costs to customers.
rated new Buy at Jefferies. $69 price target. Company delivers steady returns. Management is likely to buyback stock and add a dividend.
rated new Outperform at William Blair. Company can deliver industry-high growth.
rated new Outperform at Robert Baird. $42 price target. Company is leveraged to secular growth trends in e-commerce and can expand its margins.
This article was written by a staff member of TheStreet.